PI3K/AKT/mTOR pathway is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli important in apotopsis and hence cancer. In humans, there are three highly homologous members known as Akt1 (Uniprot P31749), Akt2 (Uniprot P31751), and Akt3 (Uniprot Q9Y243). It has been well-documented that this pathway is overactive in a number of cancers. Akt is activated by phosphorylation at the Ser473 and Thr308 positions by mTORC2 and PDK1 kinases, respectively. Faulty activation of Akt underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Constitutively activated Akt promotes cellular survival as well as resistance to treatment with chemotherapy and/or radiation therapy. In fact, several research groups are developing compounds targeting Akt as anticancer drugs. Quantitation of the expression of Akt proteins and their activated status in response to the pathway inhibitors would have great potential application in monitoring therapeutic efficacy. In part, thanks to the funding support from the National Cancer Institute (NCI Awards HHSN26100900070C) Rockland Immunochemicals has developed a suite of reagents and for measuring phosphorylation of threonine residue pT308 and serine residue pS473 of Akt applicable to monitoring the Akt responses in the presence of Akt pathway inhibitors.
Localization of AKT (Green staining) by fluorescence microscopy using rabbit anti-AKT antibody.
Localization of active AKT (red signal) in human brain cerebellum tissue using Mouse anti-AKT pT308 antibody
Western Blot using A431 cells stimulated with EGF and Mouse Anti-AKTpS473 antibody
For sandwich ELISA (E) to capture total Akt protein, rabbit raised using a C-terminal peptide and sheep pan-reactive antibody raised against an internal peptide that recognize both inactive and active forms in combination with HRP conjugated species-specific secondary antibody should be used.For Western Blotting (WB) use primary antibodies to respective targets followed with host-specific secondary antibody HRP conjugates. Use our Blocking Buffers to reduce background and to enhance sensitivity. For Immunofluorescence Microscopy (IF) use biotin conjugated antibodies in combination with streptavidin fluorescein conjugate. For Immunohistochemistry (IHC) biotin conjugated antibodies can be used with streptavidin peroxidase conjugate in combination with MaxTag™ DAB tablets.
Anti-AKT (RABBIT) Antibody
ELISA, WB, IHC, IF, FC
Anti-AKT (SHEEP) Antibody
Anti-AKT pS473 (RABBIT) Antibody
ELISA, WB, IHC, FC
Anti-AKT pT308 (MOUSE) Monoclonal Antibody
Anti-AKT pS473 (MOUSE) Monoclonal Antibody
Anti-AKT2 (RAT) Monoclonal Antibody
Anti-AKT3 (MOUSE) Monoclonal Antibody
Rockland has developed a suite of reagents to detect phosphorylated and inactive forms of AKT proteins. These reagents are applicable for profiling AKT protein expression and phosphorylated activation status allowing monitoring of the efficacy of AKT pathway anti-cancer drugs. Applications
Reagents for profiling expression and activation of AKT proteins.Advantages
AKT is activated by phosphorylation at the Ser473 and Thr308 positions by mTORC2 and PDK1 kinases, respectively. Faulty activation of AKT underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Constitutively activated AKT promotes cellular survival as well as resistance to treatment with chemotherapy and/or radiation therapy. Developed antibodies enables to rapidly quantify AKT protein expression and their phosphorylated stages in cells upon exposure to anticancer drugs, thereby allowing preclinical evaluation the anti-cancer drug efficacy and potential resistance problems. To discuss licensing or custom services opportunities please contact:Dan KenneyDirector, Scientific Business Development(484)-791-3823
Rockland Immunochemicals Inc.Limerick, PA 19468E-mail: firstname.lastname@example.orgPhone: 800.656.7625